A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength

Experimental Gerontology

Volumn 48, Issue 9, 2013, Pages 898-904

  Arounleut, Phonepasong ^a   Bialek, Peter ^b   Liang, Li Fang ^c   Upadhyay, Sunil ^a   Fulzele, Sadanand ^a   Johnson, Maribeth ^a   Elsalanty, Mohammed ^a   Isales, Carlos M ^a   Hamrick, Mark W ^a  

^a AUGUSTA UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c Tauri Group   (United States)

Author keywords

Anabolic therapy; Fractures; GDF 8; Osteoporosis; Sarcopenia

Indexed keywords

MYOSTATIN; PROTEIN INHIBITOR; RECOMBINANT MYOSTATIN PROPEPTIDE FC; UNCLASSIFIED DRUG;

AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE STRENGTH; CELL SIZE; CONTROLLED STUDY; DRUG RESPONSE; EXTENSOR DIGITORUM LONGUS MUSCLE; FEMUR; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; MUSCLE CELL; MUSCLE MASS; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; SOLEUS MUSCLE; TIBIALIS ANTERIOR MUSCLE;

ANABOLIC THERAPY; FRACTURES; GDF-8; OSTEOPOROSIS; SARCOPENIA;

AGING; ANIMALS; BODY WEIGHT; BONE DENSITY; DRUG EVALUATION, PRECLINICAL; MALE; MICE; MICE, INBRED C57BL; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOSTATIN; OSTEOGENESIS; OSTEOPOROSIS; RECOMBINANT PROTEINS; SARCOPENIA; STRESS, MECHANICAL; TIBIA; X-RAY MICROTOMOGRAPHY;

EID: 84880596613     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.06.004     Document Type: Article

References (34)

1. Bertram M., Norman R., Kemp L., Vos T. Review of the long-term disability associated with hip fractures. Inj. Prev. 2011, 17:365-370.
2. Bialek P., Parkington J., Warner L., St.Andre M., Jian L., Gavin D., Wallace C., Zhang J., Yan G., Root A., Seeherman H., Yaworsky P. Mice treated with a myostatin/GDF-8 decoy receptor, ActRIIB-Fc, exhibit a tremendous increase in bone mass. Bone 2008, 42:S46.
3. Bogdanovich S., Krag T., Barton E.R., Morris L.D., Whittemore L.A., Ahima R.S., Khurana T. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002, 420:418-421.
4. Bogdanovich S., Perkins K., Krag T., Whittemore L., Khurana T. Myostatin-propeptide mediated amelioration of dystrophic pathophysiology. FASEB J. 2005, 19:543-549.
5. Borgstein N., Condon C., Yang Y., Wilson D., Haltom E., Lachey J., Seehra J., Sherman M. Preliminary results from single subcutaneous administration of ACE-031, a form of the soluble activin typeII B receptor, in healthy postmenopausal volunteers. Neuromuscul. Disord. 2009, 19:546.
6. Bowser M., Herberg S., Arounleut P., Shi X., Fulzele S., Hill W.D., Isales C.M., Hamrick M.W. Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells. Exp. Gerontol. 2013, 48:290-297.
7. Chiu C.S., Peekhaus N., Weber H., Adamski S., Murray E.M., Zhang H.Z., Zhao J.Z., Ernst R., Lineberger J., Huang L., Hampton R., Arnold B.A., Vitelli S., Hamuro L., Wang W.R., Wei N., Dillon G.M., Miao J., Alves S.E., Glantschnig H., Wang F., Wilkinson H.A. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents. J. Gerontol. A Biol. Sci. Med. Sci. 2013, (Mar 22. [Epub ahead of print]).
8. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998, 17(11):3091-3100.
9. Digirolamo D., Singhal V., Clemens T., Lee S.-J. Systemic administration of soluble activin receptors produces differential anabolic effects in muscle and bone in mice. J. Bone Miner. Res. 2011, 1167. (Suppl.).
10. Elkasrawy M.N., Hamrick M.W. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J. Musculoskelet. Neuronal. Interact. 2010, 10:56-63.
11. Elkasrawy M.N., Fulzele S., Bowser M., Wenger K., Hamrick M.W. Myostatin (GDF-8) inhibits chondrogenesis and chondrocyte proliferation in vitro by suppressing Sox-9 expression. Growth Factors 2011, 29:253-262.
12. Elkasrawy M., Immel D., Wen X., Liu X., Liang L., Hamrick M.W. Immunolocalization of myostatin (GDF-8) following musculoskeletal injury and the effects of exogenous myostatin on muscle and bone healing. J. Histochem. Cytochem. 2012, 60:22-30.
13. Girgis C.M., Clifton-Bligh R., Hamrick M.W., Holick M.F., Gunton J.E. The roles of vitamin D in skeletal muscle: form, function and metabolism. Endocr. Rev. 2013, 34:33-83.
14. Hamrick M.W. Invited perspective: myostatin (GDF8) as a therapeutic target for the prevention of osteoporotic fractures. IBMS BoneKey. 2010, 7:8-17.
15. Hamrick M.W. A role for myokines in muscle-bone interactions. Exerc. Sport Sci. Rev. 2011, 39:43-47.
16. Hamrick M.W. The skeletal muscle secretome: an emerging player in muscle-bone crosstalk. Nat. Bonekey 2012, 60:1-5.
17. Hamrick M.W., Ding K.H., Pennington C., Chao Y.J., Wu Y.D., Howard B., Immel D., Borlongan C., McNeil P.L., Bollag W.B., Curl W.W., Yu J., Isales C.M. Age-related loss of muscle mass and bone strength in mice is associated with a decline in physical activity and serum leptin. Bone 2006, 39:845-853.
18. Hamrick M.W., Samaddar T., Pennington C., McCormick J. Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J. Bone Miner. Res. 2006, 21:477-483.
19. Hamrick M.W., Ding K.-H., Ponnala S., Ferrari S.L., Isales C.M. Caloric restriction decreases cortical bone mass but spares trabecular bone in the mouse skeleton: implications for the regulation of bone mass by body weight. J. Bone Miner. Res. 2008, 23:870-879.
20. Hamrick M.W., McNeil P.L., Patterson S.L. Role of muscle-derived growth factors in bone formation. J. Musculoskelet. Neuronal. Interact. 2010, 10:64-70.
21. Hamrick M.W., Arounleut P., Kellum E., Cain M., Immel D., Liang L. Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J. Trauma 2010, 69:579-583.
22. Jarvinen T., Sievanen H., Khan K., Heinonen A., Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ 2008, 336:124-126.
23. Jiang M.S., Liang L.F., Wang S., Ratovitski T., Holmstrom J., Barker C., Stotish R. Characterization and identification of the inhibitory domain of GDF-8 propeptide. Biochem. Biophys. Res. Commun. 2004, 315:525-531.
24. Kellum E., Starr H., Arounleut P., Immel D., Fulzele S., Wenger K., Hamrick M.W. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone 2009, 44:17-23.
25. LeBrasseur N.K., Schelhorn T.M., Bernardo B.L., Cosgrove P.G., Loria P.M., Brown T.A. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J. Gerontol. A Biol. Sci. Med. Sci. 2009, 64:940-948.
26. Lee S.J., Reed L.A., Davies M.V., Girgenrath S., Goad M.E., Tomkinson K.N., Wright J.F., Barker C., Ehrmantraut G., Holmstrom J., Trowell B., Gertz B., Jiang M.S., Sebald S.M., Matzuk M., Li E., Liang L.F., Quattlebaum E., Stotish R.L., Wolfman N.L. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18117-18122.
27. McPherron A.C. Metabolic functions of myostatin and GDF11. Immunol. Endocr. Metab. Agents Med. Chem. 2010, 10:217-231.
28. Meredith M.E., Harrison F.E., May J.M. Differential regulation of the ascorbic acid transporter SVCT2 during development and in response to ascorbic acid depletion. Biochem. Biophys. Res. Commun. 2011, 414(4):737-742.
29. Morissette M.R., Stricker C., Rosenberg M.A., Buranasombati C., Levitan E.B., Mittleman M.A., Rosenzweig A. Effects of myostatin deletion in aging mice. Aging Cell 2009, 8:573-583.
30. Murphy K., Koopman R., Naim T., Leger B., Trieu J., Ibebunjo C., Lynch G.S. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J. 2010, 24:4433-4442.
31. Sànchez-Riera L., Wilson N., Kamalaraj N., Nolla J.M., Kok C., Li Y., Macara M., Norman R., Chen J.S., Smith E.U., Sambrook P.N., Hernández C.S., Woolf A., March L. Osteoporosis and fragility fractures. Best Pract. Res. Clin. Rheumatol. 2010, 24:793-810.
32. Souza T.A., Chen X., Guo Y., Sava P., Zhang J., Hill J.J., Yaworsky P.J., Qiu Y. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol. Endocrinol. 2008, 22:2689-2702.
33. Wagner K.R., Fleckenstein J.L., Amato A.A., Barohn R.J., Bushby K., et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 2008, 63:561-571.
34. Wenger K., Fulzele S., Immel D., Chao Y., Freeman D., Elsalanty M., Powell B., Hamrick M.W., Isales C.M., Yu J. Effect of whole body vibration on bone properties in aging mice. Bone 2010, 47:746-755.